New Results
Surveying the contribution of rare variants to the genetic architecture of human disease through exome sequencing of 177,882 UK Biobank participants
Quanli Wang, View ORCID ProfileRyan S. Dhindsa, View ORCID ProfileKeren Carss, View ORCID ProfileAndrew Harper, Abhishek Nag, View ORCID ProfileIoanna Tachmazidou, View ORCID ProfileDimitrios Vitsios, View ORCID ProfileSri VV Deevi, Alex Mackay, View ORCID ProfileDaniel Muthas, Michael Hühn, View ORCID ProfileSusan Monkley, View ORCID ProfileHenric Olsson, Sebastian Wasilewski, Katherine R. Smith, View ORCID ProfileRuth March, View ORCID ProfileAdam Platt, Carolina Haefliger, View ORCID ProfileSlavé Petrovski, AstraZeneca Genomics Initiative
doi: https://doi.org/10.1101/2020.12.13.422582
Quanli Wang
1Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, USA
Ryan S. Dhindsa
1Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, USA
Keren Carss
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Andrew Harper
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Abhishek Nag
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ioanna Tachmazidou
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Dimitrios Vitsios
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Sri VV Deevi
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Alex Mackay
3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Daniel Muthas
3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Michael Hühn
3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Susan Monkley
3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Henric Olsson
3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Sebastian Wasilewski
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Katherine R. Smith
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ruth March
4Precision Medicine & Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK
Adam Platt
5Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Carolina Haefliger
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Slavé Petrovski
2Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
6Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Posted December 13, 2020.
Surveying the contribution of rare variants to the genetic architecture of human disease through exome sequencing of 177,882 UK Biobank participants
Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew Harper, Abhishek Nag, Ioanna Tachmazidou, Dimitrios Vitsios, Sri VV Deevi, Alex Mackay, Daniel Muthas, Michael Hühn, Susan Monkley, Henric Olsson, Sebastian Wasilewski, Katherine R. Smith, Ruth March, Adam Platt, Carolina Haefliger, Slavé Petrovski, AstraZeneca Genomics Initiative
bioRxiv 2020.12.13.422582; doi: https://doi.org/10.1101/2020.12.13.422582
Surveying the contribution of rare variants to the genetic architecture of human disease through exome sequencing of 177,882 UK Biobank participants
Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew Harper, Abhishek Nag, Ioanna Tachmazidou, Dimitrios Vitsios, Sri VV Deevi, Alex Mackay, Daniel Muthas, Michael Hühn, Susan Monkley, Henric Olsson, Sebastian Wasilewski, Katherine R. Smith, Ruth March, Adam Platt, Carolina Haefliger, Slavé Petrovski, AstraZeneca Genomics Initiative
bioRxiv 2020.12.13.422582; doi: https://doi.org/10.1101/2020.12.13.422582
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)